| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 200 | 96 | 9 | 8 | 4 | 4 | 9 | 12 | 4 | 11 | 3 | 3 | 7 | 2 | 5 | 4 | 10 | 5 | 5 | 8 | 9 | 16 | 9 | 7 | 5 | 7 | 3 | 3 | 3 | 5 |
| Expenses | 146 | 79 | 22 | 51 | 44 | 23 | 30 | 34 | 16 | 27 | 28 | 23 | 45 | 29 | 37 | 24 | 25 | 26 | 55 | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 |
| EBITDA | 54 | 17 | -13 | -42 | -39 | -19 | -22 | -22 | -12 | -15 | -25 | -20 | -38 | -27 | -32 | -20 | -15 | -22 | -49 | -26 | -22 | -11 | -40 | -26 | -27 | -48 | -38 | -43 | -50 | -76 |
| Operating Profit % | 24 % | 11 % | -936 % | -2,025 % | -2,635 % | -1,517 % | -999 % | -290 % | -994 % | -196 % | -1,764 % | -1,383 % | -2,118 % | -2,341 % | -733 % | -467 % | -595 % | -494 % | -1,720 % | -1,208 % | -737 % | -768 % | -1,885 % | -1,267 % | -3,023 % | -2,032 % | -2,435 % | -2,981 % | -2,714 % | -8,671 % |
| Depreciation | 6 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 47 | 11 | -14 | -44 | -40 | -20 | -23 | -23 | -13 | -17 | -26 | -22 | -39 | -28 | -34 | -21 | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 |
| Tax | 21 | 7 | 0 | -4 | -14 | -0 | 0 | 2 | -3 | -1 | -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 26 | 4 | -14 | -39 | -26 | -20 | -23 | -26 | -11 | -16 | -24 | -22 | -39 | -28 | -34 | -21 | -16 | -23 | -51 | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 |
| EPS in ₹ | 2.04 | 0.30 | -1.13 | -3.10 | -2.05 | -1.56 | -1.79 | -2.01 | -0.82 | -1.23 | -1.92 | -1.70 | -3.08 | -2.22 | -2.50 | -1.63 | -1.12 | -1.51 | -2.90 | -1.17 | -1.10 | -0.58 | -1.92 | -1.22 | -1.29 | -2.27 | -1.79 | -2.02 | -2.36 | -3.48 |
Suven Life Sciences
Suven Life Sciences
182.81
-5.21
(-2.77%)
Q1 Quarterly Results are out. Check out the updated financials1 day ago
Show All
Key Fundamentals
Market Cap
4,277.00 Cr
EPS
-7.37
PE Ratio
-19.64
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
299.99
52 Week Low
102.50
PB Ratio
14.79
Debt to Equity
0.00
Sector
Healthcare Technology Actual
Company News
View All News
Suven Life Sciences Limited submitted its monitoring agency report for the quarter ended September 30, 2025, regarding utilization of proceeds from its preferential issue of convertible warrants worth Rs 85,764.02 lakh. CRISIL Ratings Limited, the monitoring agency, reported no deviations from stated objects and confirmed all utilization was as per disclosure requirements. The company received 25% of the issue amount (Rs 21,441 lakh) during the quarter, with the remaining 75% to be received when warrant holders exercise conversion options by December 2026. Proceeds were utilized across four categories: Rs 2,616.27 lakh for clinical development through overseas subsidiary, Rs 1,172.80 lakh for drug discovery research, Rs 92.98 lakh for new R&D center infrastructure, and Rs 1,542.08 lakh for general corporate purposes. Unutilized proceeds of Rs 25,298.59 lakh were deployed in various mutual funds and money market instruments.
Suven Life Sciences reported a consolidated net loss of Rs 773 million in its quarterly results, compared to a loss of Rs 496 million in the same period last year. The loss increased by approximately 56% year-over-year.
Sunil Singhania's Abakkus Diversified Alpha Fund Holds 1.32% Stake in Suven Life ScienceOct 15, 2025
Abakkus Diversified Alpha Fund, managed by Sunil Singhania, holds a 1.32% stake in Suven Life Science as disclosed in quarterly results. This represents the fund's investment position in the pharmaceutical company.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
662.10 | #1 26,749.10 | 56.95 | #1 3,714.20 | 3.77 | #1 496 | -36.76 | 57.24 | |
514.00 | 12,218.30 | 27.69 | 2,946.50 | 10.53 | 407 | 11.34 | 34.43 | |
182.81 | #3 4,277.00 | #2 -19.64 | #7 17.60 | #9 -46.34 | #9 -161 | #6 -55.85 | 37.60 | |
642.30 | 2,869.50 | 46.55 | 322.30 | 0.22 | 41 | 112.87 | 40.40 | |
27.46 | 387.00 | 8.36 | 10.20 | #1 126.67 | 1 | #1 493.75 | 76.18 | |
99.10 | 235.00 | -4.58 | 806.50 | 4.78 | -56 | 34.67 | 51.96 | |
62.40 | 97.90 | #1 -21.99 | 47.50 | 17.87 | 0 | -100.00 | 63.61 | |
16.25 | 26.30 | 33.09 | 84.00 | 5.00 | 2 | -76.92 | 44.20 | |
26.22 | 18.60 | -1.40 | 2.10 | 40.00 | -13 | -566.67 | 20.38 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-46.34 %
Net Income Growth
52.90 %
Cash Flow Change
-33.45 %
ROE
275.61 %
ROCE
268.61 %
EBITDA Margin (Avg.)
170.98 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 773 | 752 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 |
| Fixed Assets | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 |
| Current Assets | 477 | 428 | 492 | 570 | 281 | 66 | 103 | 67 | 252 | 257 | 76 |
| Capital Work in Progress | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 |
| Other Assets | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 |
| Total Liabilities | 773 | 752 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 |
| Current Liabilities | 127 | 111 | 119 | 122 | 40 | 27 | 16 | 8 | 11 | 14 | 24 |
| Non Current Liabilities | 86 | 46 | 30 | 30 | 25 | 12 | 5 | 4 | 3 | 1 | 2 |
| Total Equity | 559 | 595 | 667 | 767 | 239 | 143 | 108 | 96 | 375 | 270 | 110 |
| Reserve & Surplus | 547 | 583 | 654 | 755 | 226 | 131 | 58 | 82 | 354 | 248 | 88 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | 0 |
| Investing Activities | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 |
| Operating Activities | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -116 | -154 |
| Financing Activities | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Nov 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Jul 2025 | Sept 2025 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 64.98 % | 64.98 % | 64.98 % | 64.98 % | 69.57 % | 69.57 % | 69.57 % | 69.57 % | 69.57 % | 69.57 % | 70.27 % | 70.27 % | 70.27 % | 70.27 % | 70.27 % | 67.43 % | 67.36 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.50 % | 0.54 % | 0.46 % | 0.45 % | 0.34 % | 0.34 % | 0.25 % | 0.59 % | 0.56 % | 1.18 % |
| DIIs | 0.21 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.13 % | 0.12 % | 0.11 % | 0.11 % | 0.08 % | 0.01 % | 0.12 % | 1.17 % | 1.17 % | 1.05 % | 1.06 % | 0.01 % | 0.02 % | 3.41 % | 3.39 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 33.92 % | 34.22 % | 33.19 % | 33.24 % | 28.69 % | 29.02 % | 27.37 % | 27.43 % | 22.98 % | 23.00 % | 23.29 % | 24.38 % | 24.05 % | 22.29 % | 22.66 % | 22.15 % | 22.31 % | 24.04 % | 23.17 % | 22.24 % | 22.25 % |
| Others | 5.87 % | 5.76 % | 6.79 % | 6.74 % | 6.31 % | 5.98 % | 7.52 % | 7.48 % | 7.34 % | 7.32 % | 7.06 % | 5.54 % | 5.72 % | 6.51 % | 5.46 % | 6.19 % | 6.04 % | 5.44 % | 5.95 % | 6.37 % | 5.82 % |
| No of Share Holders | 77,650 | 86,008 | 81,475 | 80,195 | 81,062 | 81,038 | 80,116 | 80,536 | 80,838 | 78,634 | 76,291 | 80,953 | 74,003 | 68,959 | 66,116 | 63,975 | 63,537 | 64,603 | 66,159 | 65,574 | 64,921 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1.5 | 1.5 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 12.85 | 0.57 | 7.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 18 Oct 2022 |  Rights | 1:2 | 17 Oct 2022 | 64.87 | 68.00 |
| 02 Aug 2024 |  Annual General Meeting | NA | 02 Aug 2024 | 113.45 | 143.05 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 131.40 | 121.40 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 133.25 | 122.20 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 131.05 | 152.80 |
| 05 Jun 2025 |  Extraordinary General Meeting | NA | 05 Jun 2025 | 152.80 | 234.35 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 268.80 | 233.20 |
| 22 Aug 2025 | Annual General Meeting | NA | 22 Aug 2025 | 152.80 | 234.35 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 197.45 | 187.15 |
Announcements
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication1 day ago
1 day agoUn-Audited Standalone And Consolidated Financial Results For Quarter And Half-Year Ended 30Th September 20252 days ago
2 days agoBoard Meeting Intimation for To Consider And Approve Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half-Year Ended September 30 2025 And Related Matters10 days ago
10 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 22, 2025
Aug 22, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Aug 13, 2025Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On August 13 2025Aug 13, 2025
Aug 13, 2025Board Meeting Intimation for Consider & Approve Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30 2025 And Related MattersAug 05, 2025
Aug 05, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 30, 2025
Jul 30, 2025Notice Of 36Th Annual General Meeting (AGM) Of The CompanyJul 30, 2025
Jul 30, 2025Reg. 34 (1) Annual Report.Jul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 24, 2025
Jul 24, 2025Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On Wednesday July 16 2025 - Allotment Of 9186490 Equity Shares Of The Company On Preferential Basis Upon Conversion 9186490 Fully Paid WarrantsJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Board Meeting Outcome for Allotment Of 64002999 Warrants Convertible Into Equity SharesJul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 05, 2025
Jun 05, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMJun 05, 2025
Jun 05, 2025Additional Disclosure In The Notice Of Extra-Ordinary General Meeting (EGM) Of The CompanyJun 04, 2025
Jun 04, 2025Corrigendum To Notice Of The EGM To Be Held On 05Th June 2025May 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Grant Of Stock OptionsMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Notice Of Extra-Ordinary General Meeting (EGM) Of The Company Will Be Held On Thursday June 05 2025May 14, 2025
May 14, 2025Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On Tuesday May 13 2025May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Preferential IssueMay 13, 2025
May 13, 2025Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On Tuesday May 13 2025May 13, 2025
May 13, 2025Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Tuesday The 13Th May 2025May 06, 2025
May 06, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Apr 02, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015Mar 21, 2025
Mar 21, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 26, 2025
Feb 26, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 25, 2025
Jan 25, 2025Integrated Filing (Financial)Jan 24, 2025
Jan 24, 2025No Deviation(S) Or Variation(S) In The Use Of ProceedsJan 24, 2025
Jan 24, 2025Outcome Of The Board MeetingJan 24, 2025
Jan 24, 2025Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended December 31 2024 And Related MattersJan 16, 2025
Jan 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 08, 2025
Jan 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Jan 08, 2025Closure of Trading WindowDec 27, 2024
Dec 27, 2024Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.09% | 4 | 0.00% | -0.01% | |
 Quant Business Cycle Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
| Quant Healthcare Fund Direct - Growth | 0.00% | 0 | 0.00% | 0.00% | |
| Quant Small Cap Fund Direct Plan-Growth | 0.30% | 0 | -0.02% | -0.05% |
Technical Indicators
RSI(14)
Neutral 41.06
ATR(14)
Volatile 8.09
STOCH(9,6)
Oversold 16.08
STOCH RSI(14)
Oversold 18.83
MACD(12,26)
Bearish -0.20
ADX(14)
Weak Trend 14.54
UO(9)
Bearish 39.09
ROC(12)
Downtrend And Accelerating -5.83
WillR(14)
Neutral -73.86
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
